|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
RMX1002单药及联合PD-1单抗治疗晚期实体瘤患者的剂量递增及扩展的药代动力学、耐受性、初步有效性评估的I期临床
主要目的:RMX1002单药、RMX1002联合PD-1单抗治疗晚期实体瘤患者的安全性及耐受性,确定MTD和/或后期推荐剂量; 次要目的:RMX1002、RMX1002联合PD-1单抗在晚期实体瘤患者体内的PK特征、初步疗效、安全性及耐受性; 探索性: PD指标与RMX1002、RMX1002联合PD-1单抗疗效的潜在关系;生物标志物与RMX1002联合PD-1单抗治疗方案预后的相关性
100 项与 宁波新湾医药科技有限公司 相关的临床结果
0 项与 宁波新湾医药科技有限公司 相关的专利(医药)
100 项与 宁波新湾医药科技有限公司 相关的药物交易
100 项与 宁波新湾医药科技有限公司 相关的转化医学